Microtubules as a target in cancer therapy

Cytoskeleton and Human Disease

Volumn 9781617797880, Issue , 2012, Pages 203-221

  Risinger, April L ^a   Mooberry, Susan L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84898845367     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-61779-788-0_11     Document Type: Chapter

References (123)

1. Johnson IS et al (1963) The vinca alkaloids: A new class of oncolytic agents. Cancer Res 23:1390-1427
2. Frampton JE, Moen MD (2010) Vinflunine. Drugs 70(10):1283-1293
3. Clinicaltrials.gov (2010). United States National Institutes of Health Clinical trials http://www.clinicaltrials.gov. Accessed October 5th, 2010
4. Downing KH, Nogales E (1999) Crystallographic structure of tubulin: implications for dynamics and drug binding. Cell Struct Funct 24(5):269-275
5. Wilson L et al (1982) Interaction of vinblastine with steady-state microtubules in vitro. J Mol Biol 159(1):125-149
6. Jordan MA,Wilson L (1990) Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations. Biochemistry 29(11):2730-2739
7. Jordan MA, Kamath K (2007) How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 7(8):730-742
8. Singer WD et al (1989) Binding of vinblastine to stabilized microtubules. Mol Pharmacol 36(3):366-370
9. Dhamodharan R et al (1995) Vinblastine suppresses dynamics of individual microtubules in living interphase cells. Mol Biol Cell 6(9):1215-1229
10. Jordan MA, Thrower D, Wilson L (1991) Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 51(8):2212-2222
11. Ngan VK et al (2000) Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 60(18):5045-5051
12. Ngan VK et al (2001) Mechanism of mitotic block and inhibition of cell proliferation by the semisyntheticVinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 60(1):225-232
13. Holwell SE, Hill BT, Bibby MC (2001) Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer 84(2):290-295
14. Smith JA et al (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49(6):1331-1337
15. Bai RL et al (1991) Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 266(24):15882-15889
16. Jordan MA et al (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4(7):1086-1095
17. Vahdat LT et al (2009) Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27(18):2954-2961
18. Alley SC, Okeley NM, Senter PD (2010) Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 14(4):529-537
19. Issell BF, Crooke ST (1978) Maytansine. Cancer Treat Rev 5(4):199-207
20. Lewis PhillipsGDet al (2008)Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68(22):9280-9290
21. Galsky MD et al (2008) Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 26(13):2147-2154
22. Pettit GR (1997) The dolastatins. Fortschr Chem Org Naturst 70:1-79
23. Luesch H et al (2001) Isolation of dolastatin 10 from the marine cyanobacterium Symploca speciesVP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J Nat Prod 64(7):907-910
24. Pitot HC et al (1999) Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 5(3):525-531
25. Vaishampayan U et al (2000) Phase II study of dolastatin-10 in patients with hormonerefractory metastatic prostate adenocarcinoma. Clin Cancer Res 6(11):4205-4208
26. Anderson HJ et al (1997) Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother Pharmacol 39(3):223-236
27. Edelman MJ et al (2003) Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer 39(2):197-199
28. Kuznetsov G et al (2009) Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Mol Cancer Ther 8(10):2852-2860
29. Hamel E (2002) Interactions of antimitotic peptides and depsipeptides with tubulin. Biopolymers 66(3):142-160
30. Hamel E (1992) Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 55(1):31-51
31. Wani MC et al (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93(9):2325-2357
32. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277(5698):665-667
33. Kumar N (1981) Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256(20):10435-10441
34. Derry WB, Wilson L, Jordan MA (1995) Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 34(7):2203-2211
35. Nogales E et al (1995) Structure of tubulin at 6.5-A and location of the taxol-binding site. Nature 375(6530):424-427
36. Elie-Caille C et al (2007) Straight GDP-tubulin protofilaments form in the presence of taxol. Curr Biol 17(20):1765-1770
37. BueyRMet al (2007) Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites. Nat Chem Biol 3(2):117-125
38. Barasoain I et al (2010) Probing the pore drug binding site of microtubules with fluorescent taxanes: evidence of two binding poses. Chem Biol 17(3):243-253
39. Kamath K, Jordan MA (2003) Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res 63(18):6026-6031
40. Jordan MA et al (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 90(20):9552-9556
41. Chen JG, Horwitz SB (2002) Differential mitotic responses to microtubule-stabilizing and-destabilizing drugs. Cancer Res 62(7):1935-1938
42. Piperno G, LeDizet M, Chang XJ (1987) Microtubules containing acetylated alpha-tubulin in mammalian cells in culture. J Cell Biol 104(2):289-302
43. Mooberry SL et al (2004) Microtubule-stabilizing agents based on designed laulimalide analogues. Proc Natl Acad Sci U S A 101(23):8803-8808
44. JordanMAet al (1996) Mitotic block induced in HeLa cells by lowconcentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56(4):816-825
45. Horwitz SB (2004) Personal recollections on the early development of taxol. J Nat Prod 67(2):136-138
46. Joyce C (1993) Taxol: search for a cancer drug. Bioscience 43(3):133-136
47. Nicolaou KC et al (1994) Total synthesis of taxol. Nature 367(6464):630-634
48. Tabata H (2006) Production of paclitaxel and the related taxanes by cell suspension cultures of Taxus species. Curr Drug Targets 7(4):453-461
49. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332(15):1004-1014
50. Miele E et al (2009) Albumin-bound formulation of paclitaxel (abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine 4:99-105
51. Gradishar WJ et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794-7803
52. Di LorenzoGet al (2010) Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs. 70(8):983-1000
53. Shionoya M et al (2003) DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 94(5):459-466
54. Sampath D et al (2003) MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol Cancer Ther 2(9):873-884
55. Bollag DM et al (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55(11):2325-2333
56. Kowalski RJ, Giannakakou P, Hamel E (1997) Activities of the microtubule-stabilizing agents epothilonesA and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 272(4):2534-2541
57. Wartmann M, Altmann KH (2002) The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2(1):123-148
58. Giannakakou P et al (2000)A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc NatlAcad Sci U S A 97(6):2904-2909
59. Verrills NM et al (2003) Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol 10(7):597-607
60. Bode CJ et al (2002) Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 41(12):3870-3874
61. Nettles JH et al (2004) The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science 305(5685):866-869
62. Gapud EJ et al (2004) Laulimalide and paclitaxel: A comparison of their effects on tubulin assembly and their synergistic action when present simultaneously. Mol Pharmacol 66(1):113-121
63. Hunt JT (2009) Discovery of ixabepilone. Mol Cancer Ther 8(2):275-281
64. Padzur R, Keegan P (2007) FDA approval for Ixabepilone. In: N.C. Institute (ed) Cancer topics. www.cancer.gov.cancertopics/druginfo/fda-ixbepilone. Accessed October 5th, 2010
65. FryeDK(2010)Advances in breast cancer treatment: The emerging role of ixabepilone. Expert Rev Anticancer Ther 10(1):23-32
66. Shen H, Lee FY, Gan J (2011) Lxabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 337(2): 423-432
67. Goodin S, KaneMP, RubinEH(2004) Epothilones: mechanism of action and biologic activity. J Clin Oncol 22(10):2015-2025
68. Gunasekera SP, Gunasekera M, Longley RE (1990) Discodermolide: A new bioactive polyhydroxylated lactone from the marine sponge discodermia dissoluta. J Org Chem 55:4912-4915
69. ter Haar E et al (1996) Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 35(1):243-250
70. Kowalski RJ et al (1997) The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 52(4):613-622
71. Honore S et al (2003) Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation. Mol Cancer Ther 2(12):1303-1311
72. Honore S et al (2004) Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res 64:4957-4964
73. Martello LA et al (2000) Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 6(5):1978-1987
74. Mita A et al (2004) A phase I pharmacokinetic (PK) trial of XAA296A (discodermolide) administered every 3 wks to adult patients with advanced solid malignancies. J Clin Oncol 22(14S):2025
75. Buey RM et al (2005) Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the Paclitaxel site predicts cytotoxicity. Chem Biol 12(12):1269-1279
76. Quinoa E, KakouY, Crews P (1988) Fijianolides, polyketide structures form a marine sponge. J Org Chem 53:3642-3644
77. Corley DG et al (1988) Laulimalides: new potent cytotoxic macrolides from a marine sponge and a nudibranch predator. J Org Chem 53:3644-3646
78. Mooberry SL et al (1999) Laulimalide and isolaulimalide, new paclitaxel-like microtubulestabilizing agents. Cancer Res 59(3):653-660
79. Pryor DE et al (2002) The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 41(29):9109-9115
80. Liu J et al (2007) In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res 27(3B):1509-1518
81. Mooberry SL et al (2008) Function-oriented synthesis: biological evaluation of laulimalide analogues derived from a last step cross metathesis diversification strategy. Mol Pharm 5(5):829-838
82. Mulzer J, Ohler E (2003) Microtubule-stabilizing marine metabolite laulimalide and its derivatives: synthetic approaches and antitumor activity. Chem Rev 103(9):3753-3786
83. BennettMJet al (2010) Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. Chem Biol 17(7):725-734
84. Clark EA et al (2006) Laulimalide and synthetic laulimalide analogues are synergistic with paclitaxel and 2-methoxyestradiol. Mol Pharm 3(4):457-467
85. Johnson TA et al (2007) Sponge-derived fijianolide polyketide class: further evaluation of their structural and cytotoxicity properties. J Med Chem 50(16):3795-3803
86. West LM, Northcote PT, Battershill CN (2000) Peloruside A: A potent cytotoxic macrolide isolated from the new zealand marine sponge Mycale sp. J Org Chem 65(2):445-449
87. HoodKAet al (2002) PelorusideA, a novel antimitotic agent with paclitaxel-like microtubulestabilizing activity. Cancer Res 62(12):3356-3360
88. Gaitanos TN et al (2004) Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res 64(15):5063-5067
89. Wilmes A et al (2010) Synergistic interactions between peloruside A and other microtubulestabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells. Cancer Chemother Pharmacol 68(1):117-126
90. Chen Z, Shen J, GaoY(1989) Some chemical reactions of taccalonolideA-abitter substance from Tacca plantaginea. Heterocycles 29:2103-2108
91. Tinley TL et al (2003) Taccalonolides E and A: Plant-derived steroids with microtubulestabilizing activity. Cancer Res 63(12):3211-3220
92. Risinger AL, Mooberry SL (2011) Cellular studies reveal mechanistic differences between taccalonolide A and paclitaxel. Cell Cycle 10(13):2162-2171
93. Li J et al (2011) Potent taccalonolides, AF and AJ, inform significant structure-activity relationships and tubulin as the binding site of these microtubule stabilizers. J Am Chem Soc 133(47): 19064-19067
94. RisingerAL et al (2008) The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res 68(21):8881-8888
95. RisingerAL, Mooberry SL (2010) Taccalonolides: Novel microtubule stabilizers with clinical potential. Cancer Lett 291(1):14-19
96. Colchicine (marketed as Colcrys) (2009 August 03, 2010) http://www.fda.gov/Safety/Med Watch/SafetyInformation/SafetyAlertsforHumanMedicalPRoducts/ucm174596.htm. Accessed 26 August 2010
97. Downing KH, Nogales E (1998) New insights into microtubule structure and function from the atomic model of tubulin. Eur Biophys J 27(5):431-436
98. Skoufias DA, Wilson L (1992) Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes. Biochemistry 31(3):738-746
99. Bhattacharyya B et al (2008) Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 28(1):155-183
100. Chaudhary A et al (2007) Combretastatin a-4 analogs as anticancer agents. Mini Rev Med Chem 7(12):1186-1205
101. Lin CM et al (1988) Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: A structure-activity study. Mol Pharmacol 34(2):200-208
102. Pettit GR et al (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45(2):209-211
103. McGown AT, Fox BW (1989) Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des 3(4):249-254
104. Giavazzi R, Bonezzi K, Taraboletti G (2008) Microtubule targeting agents and the tumor vasculature. In: Fojo T (ed) Cancer drug discovery and development: The role of microtubules in cell biology, neurobiology, and oncology. Humana Press, Totowa, pp 519-530
105. Horsman MR, Siemann DW(2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66(24):11520-11539
106. Boyland E, Boyland ME (1937) Studies in tissue metabolism: The action of colchicine and B. typhosus extract. Biochem J 31(3):454-460
107. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5(6):423-435
108. Baluk P, Hashizume H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15(1):102-111
109. Mutsaers AJ (2009) Metronomic chemotherapy. Top Companion Anim Med 24(3):137-143
110. Vacca A et al (1999) Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94(12):4143-4155
111. Grant DS et al (2003) Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 104(1):121-129
112. Rajkumar SV et al (2007) Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res 13(20):6162-6167
113. Pasquier E et al (2010) ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther 9(5):1408-1418
114. Orth JD et al (2011) Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. Cancer Res 71(13): 4608-4616
115. Komlodi-Pasztor E et al (2011) Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 8(4): 244-250
116. Kingston DG (2009) Tubulin-interactive natural products as anticancer agents. J Nat Prod 72(3):507-515
117. Cortes J et al (2010) Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 28(25):3922-3928
118. Gangjee A et al (2011) Corrections to synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent pgp mediated resistance. J Med Chem
119. Baas P et al (2008) Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. J Thorac Oncol 3(7):745-750
120. Fishman MN et al (2006) Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies. Clin Cancer Res 12(2):523-528
121. Ramanathan RK et al (2008) A phase II study of milataxel: A novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemother Pharmacol 61(3):453-458
122. Cheng KL, Bradley T, Budman DR (2008) Novel microtubule-targeting agents-The epothilones. Biologics 2(4):789-811
123. Isbrucker RA et al (2003) Tubulin polymerizing activity of dictyostatin-1, a polyketide of marine sponge origin. Biochem Pharmacol 66(1):75-82